N/A N=121 Promoting Viral Suppression Among Transgender Women Living With HIV in Santo Domingo
HIV
Primary: Number of Participants With Viral Suppression (HIV), 6 Months — 31; 33 Participants — p=0.489
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=133 Evaluation of Delefilcon A and Senofilcon A Daily Disposable Toric Soft Contact Lenses Over One Week of Wear
Astigmatism
Primary: Long Lasting Comfort — 100; 62; 33; 71 Participants — p=<0.001
Phase 1 N=56 A Study in Healthy Japanese Men to Test How Different Doses of BI 1569912 Are Taken up by the Body and How Well They Are Tolerated
Healthy
Primary: SRD Part - Number of Subjects With Drug-related Adverse Events — 0; 0; 0; 0 Participants
N/A N=20 Evaluation of the Delivery of Optimized Supersaturated Oxygen Therapy to Treat Patients With an Acute Heart Attack
Anterior Wall Acute Myocardial Infarction
Primary: The Feasibility of Intracoronary Infusion of SSO2 Therapy — 20 participants
Phase 2 N=49 Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma
Adult Lymphocyte Depletion Hodgkin Lymphoma · Adult Lymphocyte Predominant Hodgkin Lymphoma · Adult Mixed Cellularity Hodgkin Lymphoma
Primary: Complete Remission Rate After Chemotherapy — 38 Participants
N/A N=466 The EMBER Trial for Weight Management Engagement
Obesity
Primary: Weight Management Use — 89; 42 Participants
N/A N=327 Prospective Evaluation of Biliary Tissue Sampling With ERCP
Cholangiopancreatography, Endoscopic Retrograde · Biliary Stricture · Biliary Tract Diseases
Primary: Performance Characteristics — 84.09; 56.98; 94.87 Percentage
Phase 3 N=277 Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)
Active Systemic Lupus Erythematosus
Primary: Difference in Proportion of Participants Who Are Responders Between Anifrolumab and Placebo — 84; 46 Participants — p=>0.999
N/A N=441 Bedside Improvement of Resuscitation Through mHealth Feedback (BIRTH Study)
Respiratory Depression Neonatal
Primary: Mean Duration of Suctioning Among All Live Births — 21.9; 15.7; 34.1; 23.2 seconds
N/A N=324 The LEADLESS II IDE Study for the Aveir VR Leadless Pacemaker System
Cardiac Rhythm Disorder · Bradycardia
Primary: Complication-Free Rate (CFR) — 96.0 percentage of participants — p=<0.0001
Phase 2 N=20 Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Progression-Free Survival Rate at 6 Months From Start of Study Treatment (Maintenance Pembrolizumab) — 5.0 Percentage of participants
Phase 3 N=139 A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma
Non-infectious Anterior Uveitis · Uveitic Glaucoma
Primary: Anterior Chamber Cell (ACC) Grade = 0 on Day 28 — 38; 32; 44; 15 Participants
N/A N=29 Medical Cannabis as an Opiate Alternative
Chronic Pain · Opioid Use
Primary: Change in Mean Numeric Rating Scale at 5 Months From Baseline — -1.5 Units on a 0-10 scale
Phase 1 N=43 3BNC117-LS First-in-Human Phase 1 Study
Human Immunodeficiency Virus
Primary: The Number of Participants Who Experience Adverse Events Within 2 Weeks After 3BNC117-LS Infusion in All Study Groups — 0; 0; 1; 0 Participants
N/A N=30 Developing and Testing the Enhancing Active Caregiver Training (EnACT) Intervention for Dementia Family Caregivers
Dementia, Familial
Primary: Imagined Interactions: Specificity — 16.87; 16.33; 16.49; 16.20 Scores on a scale — p=0.70